Compass Pathways PLC (NASDAQ:CMPS) said a White House executive order aimed at accelerating mental health treatment research could help speed access to its experimental psilocybin therapy, which the company says has shown fast and durable results in late-stage clinical trials for treatment-resistant depression.
White House Order Boosts Psychedelic Drug Momentum
The biotechnology company Compass Pathways welcomed the Trump administration’s move, calling it an important step toward addressing the mental health crisis.
Compass CEO Kabir Nath said the executive order “recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could have.”
Nath said the policy “aligns regulatory urgency with patient need” and supports “accelerating access, without compromising rigorous science.”
He added that the company’s synthetic psilocybin drug, COMP360, has shown “highly statistically significant and clinically meaningful data” in Phase 3 trials for treatment-resistant depression.
The company said …
This post was originally published here
